MediGene AG Share Price Xetra
Equities
DE0005020903
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Sales 2024 * | 10.6M 11.55M 891M | Sales 2025 * | 6.95M 7.58M 584M | Capitalization | 34.79M 37.92M 2.92B |
---|---|---|---|---|---|
Net income 2024 * | -11M -11.99M -924M | Net income 2025 * | -17M -18.53M -1.43B | EV / Sales 2024 * | 4.89 x |
Net Debt 2024 * | 17M 18.53M 1.43B | Net Debt 2025 * | 14M 15.26M 1.18B | EV / Sales 2025 * | 7.02 x |
P/E ratio 2024 * |
-3.19
x | P/E ratio 2025 * |
-2.11
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.05% |
Latest transcript on MediGene AG
Managers | Title | Age | Since |
---|---|---|---|
Selwyn Ho
CEO | Chief Executive Officer | 53 | 24/07/22 |
Dolores Schendel
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/14 |
Pamela Keck
IRC | Investor Relations Contact | - | 31/01/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 11/08/16 | |
Frank Mathias
BRD | Director/Board Member | 62 | 14/05/18 |
Anthony Man
BRD | Director/Board Member | 68 | 15/12/20 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |